3SBio Inc. (FRA:83B)

Market Cap	8.41B
Revenue (ttm)	1.21B
Net Income (ttm)	276.61M
Shares Out	n/a
EPS (ttm)	0.11
PE Ratio	30.39
Forward PE	29.15
Dividend	0.03 (0.76%)
Ex-Dividend Date	Jul 21, 2025

Volume	2,100
Average Volume	1,697
Open	3.540
Previous Close	3.440
Day's Range	3.540 - 3.660
52-Week Range	0.570 - 3.660
Beta	n/a
RSI	64.09
Earnings Date	Aug 22, 2025

About 3SBio

3SBio Inc., an investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; and Cipterbin, an anti-HER2 monoclonal antibody for the treatment of advanced HER2-positive breast cancer and pan-HER2. It also offers Yisaipu, the receptor fusion tumor necrosis factor inhibitor; EPIAO and SEPO, an erythropoietin injection; Mandi-minoxidil, an OTC ex...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1993
• Employees: 5,577
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 83B

Financial Performance

In 2024, 3SBio's revenue was 9.11 billion, an increase of 16.53% compared to the previous year's 7.82 billion. Earnings were 2.09 billion, an increase of 34.93%.

Financial numbers in CNY